Thymus Carcinoma

subtype

Identifier: CI-CAN-00001578
Entity page: /cancer/thymus-carcinoma ↗
Edges: 85

Neighbours: 1 genes1 variants25 drugs10 trials
Drawn: 37 of 37 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Thymus Carcinoma predicts response to …PREDICTS_RESPONSE_TO1 of 1
in context · predicts response to	KIT V560DELdeletion → predicts response to Imatinib	sensitivity	C	Thymus Carcinoma	1	Curated	civic	graph →
Thymus Carcinoma associated with …ASSOCIATED_WITH

Thymus Carcinoma investigated for …INVESTIGATED_FOR1 of 1
← investigated for	Imatinibsmall_molecule	supports	C	Thymus Carcinoma	1	Curated	civic	graph →

Thymus Carcinoma investigated for …INVESTIGATED_FOR1 of 1

← investigated for

Imatinibsmall_molecule

supports

Thymus Carcinoma

Curated

Thymus Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived24 of 24show fewer
→ investigated in trials for	Pembrolizumabmonoclonal antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Akt Inhibitor MK2206 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Amrubicinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Belinostatsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Celecoxibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lapatinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lucitanibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sacituzumab Govitecanadc 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Selumetinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →

Thymus Carcinoma studied in …STUDIED_INderived10 of 58show all (up to 200)
→ studied in	NCT03076554Phase 2 · active not recruiting A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 58 trials mapped (24 active)	—	—	Thymus Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06980077Phase 2 · recruiting Ivonescimab for the Treatment of Thymic Cancer · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07824505Phase 2 · completed Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06248515Phase 2 · recruiting A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07181720Phase 1 · suspended CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07324629Phase 2 · recruiting Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03463460Phase 2 · active not recruiting Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07750353Phase 2 · not yet recruiting A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01025089Phase 2 · active not recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma · condition mapped CURATED_BROADER · 58 trials mapped (24 active)	—	—	Thymus Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains